HEALTH
Diagnostek Stockholders Sue Over Acquisition Offer: The shareholders filed 11 lawsuits seeking to block Value Health Inc.’s $527-million acquisition of the prescription drug benefits manager. The plaintiffs, who are seeking class-action status, contend that Albuquerque, N.M.-based Diagnostek Inc.’s board breached its fiduciary responsibility by agreeing to sell the company for too low a price. Value Health, based in Avon, Conn., said Monday that it had agreed to buy Diagnostek for stock currently valued at about $527 million. Diagnostek officials could not be reached for comment.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.